SDZ WAG 994

CAS : 130714-47-5

Ref. 3D-FFA71447

Informations sur le produit

• Nom: SDZ WAG 994
• Synonymes: N(6)-cyclohexyl-2-O-methyladenosine, N-cyclohexyl-2'-O-methyladenosine

Description

SDZ WAG 994 is an experimental drug that has been shown to reduce the incidence of diabetic cardiomyopathy. It is a small molecule with a molecular weight of 514.3 Da and an adenosine receptor agonist activity. SDZ WAG 994 binds to adenosine receptors, which are found in the heart and brain. These receptors are involved in locomotion, pain sensation, and cardiac function. The binding of SDZ WAG 994 to these receptors leads to increased levels of cAMP, which is necessary for cell growth and proliferation. In addition, SDZ WAG 994 has been shown to have anti-inflammatory properties that may be useful in treating chronic pain caused by damaged tissue.
SDZ WAG 994 was evaluated as a treatment for ventricular dysfunction in patients with type 2 diabetes mellitus (T2DM) using a randomized controlled trial design in which subjects were given either placebo or 50 mg/day of SDZ WAG 9

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 363.41 g/mol
• Formule: C₁₇H₂₅N₅O₄
• Degré de pureté: Min. 95%